InvestorsHub Logo
Followers 93
Posts 8868
Boards Moderated 0
Alias Born 05/06/2014

Re: None

Friday, 03/09/2018 2:16:20 PM

Friday, March 09, 2018 2:16:20 PM

Post# of 73517


I'm surprised Otiko is still stating the company is using the technology invented by Phillips (later acquired by Keough) in their OTC Profile. We know that Otiko was never the inventor.

Yeah, I know he thinks he can patent it by filing a provisional patent because Phillips never pursued the Grant once his application was published. Will he ever see his provisional patent become a published application and then a Granted Patent if Keough has a registered Trademark on a product developed with the same core technology?

I recall reading that Otiko filed for a different patent. Then why is he using Phillips name?

SMH - Hope Keough refiles his lawsuit in CA. Otiko needs to be held accountable.

ViaDerma, Inc. is a pharmaceutical company committed to bringing new products to the pharmaceutical industry through innovative research and development. The Company manufactures and sells products in fields of medicine ranging from infectious diseases to stem-cell therapy. The Company?s products are normally applied topically using a patent-pending delivery system technology created by Dr. Phillips and Dr. Chris Ayo Otiko. Presently, the products are used within the OTC drug market, i.e. non-prescription. However, the Company believes the delivery system can be used for the prescription medication market as well not only for topical prescription medications but also to turn certain oral medications into topically based medications. In addition to the primary plan of developing and selling new products to the market, the Company is exploring the possibility of licensing the technology to other pharmaceutical companies.



https://www.otcmarkets.com/stock/VDRM/profile